Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betibeglogene autotemcel - bluebird bio

Next Previous
X
Search
Drug Profile

Betibeglogene autotemcel - bluebird bio

Alternative Names: Autologous CD34+ cells encoding βA-T87Q-globin gene therapy - bluebird bio; bb1111; BB305-beta-A(T87Q)-globin-gene-therapy-bluebird-bio; Beta-globin-gene-therapy-bluebird-bio; beti-cel; HPV569-beta-A(T87Q)-globin-gene-therapy-bluebird-bio; HPV569-beta-globin-gene-therapy-bluebird-bio; LentiGlobin gene therapy; LentiGlobin-HPV569; LentiGlobin™ bb1111; LentiGlobin™ BB305; Lentiviral beta AT87Q-Globin vector; lovo-cel; Lovotibeglogene autotemcel - bluebird bio; LYFGENIA; ZYNTEGLO; Zynteglo

Latest Information Update: 21 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genetix Pharmaceuticals
  • Developer bluebird bio
  • Class Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 14 Aug 2024 Launched for Beta-thalassaemia (In adolescents, In children, In infants, In neonates, In adults) in USA (IV) prior to August 2024
  • 14 Aug 2024 Launched for Sickle cell anaemia (In adolescents, In children, In adults) in USA (IV) prior to August 2024
  • 30 Jan 2024 bluebird bio completes a phase I/II HGB-206 trial in Sickle cell anaemia in the USA (NCT02140554)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top